<DOC>
	<DOCNO>NCT03099096</DOCNO>
	<brief_summary>This study aim assess correct real-world use autoinjector repeat self-administration mepolizumab SC , improve subject / physician convenience enable repeat dose self injection via caregiver . This Phase III study open-label , single-arm , repeat-dose , multi-centre study mepolizumab liquid drug product autoinjector ( 100 milligram [ mg ] ) administer subcutaneously ( SC ) every 4 week ( 3 dos ) subject severe eosinophilic asthma . Subjects receive 100 mg mepolizumab SC single injection self-administered thigh , abdomen administer upper arm ( caregiver ) . Each subject participate study 18 week include pre-screening visit , screen visit 12-week treatment period conclude end study assessment ( Visit 5 ) 4 week last dose mepolizumab . Approximately 158 subject enrol study .</brief_summary>
	<brief_title>Study Mepolizumab Autoinjector Asthmatics</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Age : At least 12 year age inclusive , time signing informed consent . For country local regulation permit enrolment adult , subject recruitment restrict &gt; =18 year age . Asthma : A physician diagnosis asthma &gt; =2 year meet National Heart , Lung Blood Institute guideline Global Initiative Asthma guideline . Mepolizumab treatment : . Not receive mepolizumab treatment Visit 1 . These subject must also meet follow inclusion criterion relate eosinophilic asthma , inhale corticosteroid , controller medication exacerbation history ) : Eosinophilic asthma : A high likelihood eosinophilic asthma per require 'Continuation Treatment'criterion , Inhaled corticosteroid : A welldocumented requirement regular treatment high dose inhale corticosteroid ( ICS ) 12 month prior Visit 1 without maintenance oral corticosteroid ( OCS ) , subject &gt; =18 year old , ICS dose must &gt; =880 microgram ( mcg ) /day fluticasone propionate ( FP ) ( exactuator ) equivalent daily , For ICS/longactingbeta2agonist ( LABA ) combination preparation , high approve maintenance dose local country meet ICS criterion , subject &gt; =12 &lt; =17 year old , ICS dose must &gt; =440 mcg/day FP ( exactuator ) equivalent daily , ICS/LABA combination preparation , midstrength approve maintenance dose local country meet ICS criterion . ( Subjects permit enrol without continuous high dose ICS provide subject receive continuous ICS Investigator attest subject treat high dose ICS mitigate risk exacerbation , subject financial tolerance issue prevent use highdose ICS . Such subject discuss GSK Medical Monitor prior enrolment ) Controller medication : Current treatment additional controller medication , besides ICS , least 3 month document failure past 12 month additional controller medication ( e.g. , LABA , leukotriene receptor antagonist [ LTRA ] , theophylline ) least 3 successive month . Exacerbation history : Previously confirm history one exacerbations require treatment systemic corticosteroid ( CS ) [ intramuscular ( IM ) , intravenous , oral ] 12 month prior Visit 1 , despite use highdose ICS . For subject receive maintenance CS , CS treatment exacerbation must twofold dose increase great . , b . Receiving 100 mg SC mepolizumab administer treatment severe eosinophilic asthma every 4 week least 12 week prior Visit 1 . Body weight : A minimum body weight &gt; =40 kilogram ( kg ) Visit 1 Gender : Male female . A female subject eligible participate pregnant ( confirm negative urine human chorionic gonadotrophin [ hCG ) ] test ) , plan become pregnant time study participation ( 16 week last dose ) , lactate , least one follow condition applies : Nonreproductive potential define : premenopausal female document tubal ligation document hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion hysterectomy document bilateral oophorectomy , postmenopausal female , reproductive potential agrees follow highly effective method avoid pregnancy female reproductive potential 30 day prior first dose study medication 16 week last dose study medication completion end study/early withdrawal visit . The investigator responsible ensure subject understand properly use method contraception . Informed consent : Capable give sign informed consent . Concurrent respiratory disease : Presence know preexisting , clinically important lung condition asthma . This include current infection , bronchiectasis , pulmonary fibrosis , bronchopulmonary aspergillosis , diagnose emphysema chronic bronchitis ( chronic obstructive pulmonary disease asthma ) history lung cancer . Eosinophilic disease : Subjects condition could lead elevate eosinophils hypereosinophilic syndrome , include churgstrauss syndrome , eosinophilic esophagitis . Subjects know , preexist parasitic infestation within 6 month prior Visit 1 also exclude . Malignancy : A current malignancy previous history cancer remission le 12 month prior screen . Subjects localize carcinoma skin resect cure exclude . Immunodeficiency : A known immunodeficiency ( e.g . human immunodeficiency virus [ HIV ] ) , explain use corticosteroid take therapy asthma . Other concurrent medical condition : Subjects know , preexist , clinically significant cardiovascular , endocrine , autoimmune , metabolic , neurological , renal , gastrointestinal , hepatic , haematological system abnormality uncontrolled standard treatment . Liver disease : Known , preexist , unstable liver disease ( define presence ascites , encephalopathy , coagulopathy , hypoalbuminaemia , esophageal gastric varix persistent jaundice ) , cirrhosis , know biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . ECG assessment : QT interval correct heart rate either Fridericia 's Bazett 's formula ( QTc [ F ] QTc [ B ] ) &gt; =450 millisecond ( msec ) QTc ( F ) QTc ( B ) &gt; =480 msec subject bundle branch block Visit 1 . Xolair : Subjects receive omalizumab within 130 day Visit 1 . Other monoclonal antibody include mepolizumab : Subjects receive monoclonal antibody treat inflammatory disease within 5 halflives Visit 1 . Investigational medication : Subjects receive treatment investigational drug , mepolizumab within past 30 day five terminal phase halflives drug whichever longer , prior visit 1 ( also include investigational formulation market product ) experimental antiinflammatory drug ( non biologicals ) past 3 month . Chemotherapy : Subjects receive chemotherapy within 12 month prior Visit 1 . Alcohol/substance abuse : A history ( suspected history ) alcohol misuse substance abuse within 2 year prior Visit 1 . Hypersensitivity : Subjects hypersensitivity mepolizumab excipients ( sodium phosphate , citric acid , sucrose , ethylenediaminetetraacetic acid [ EDTA ] , polysorbate 80 ) . Adherence : Subjects know evidence lack adherence controller medication and/or ability follow physician 's recommendation .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>SB240563</keyword>
	<keyword>Mepolizumab</keyword>
	<keyword>self-administration</keyword>
	<keyword>eosinophilic asthma</keyword>
	<keyword>autoinjector</keyword>
</DOC>